This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 16th
by Zacks Equity Research
ALB, AAL and AQST have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2024.
New Strong Sell Stocks for July 11th
by Zacks Equity Research
AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024.
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -88.89% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
by Zacks Equity Research
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
by Zacks Equity Research
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -50% and 12.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Bulls Look Optimistic About Aquestive Therapeutics (AQST): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Aquestive Therapeutics (AQST). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Aquestive Therapeutics (AQST) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed the most recent trading day at $3.67, moving +0.55% from the previous trading session.
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.
Aquestive Therapeutics (AQST) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.65, marking a -1.67% move from the previous day.
Aquestive Therapeutics (AQST) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.68, representing a +1.13% change from its previous close.
Why Aquestive Therapeutics (AQST) Outpaced the Stock Market Today
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.52% move from the prior day.
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Aquestive Therapeutics (AQST) reachead $2.63 at the closing of the latest trading day, reflecting a -1.5% change compared to its last close.
Aquestive Therapeutics (AQST) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) reachead $2.39 at the closing of the latest trading day, reflecting a +0.84% change compared to its last close.
Aquestive Therapeutics (AQST) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.50, representing a -0.4% change from its previous close.
Aquestive Therapeutics (AQST) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Aquestive Therapeutics (AQST) closed at $2.63 in the latest trading session, marking a -1.13% move from the prior day.